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Case presentation
A 61-year-old white man was admitted to the Iowa City Veterans
Administration Medical Center for increasing abdominal girth and
swelling of the legs over 2 weeks; he also noticed darkening of his urine
as well as yellow skin and eyes. The patient, known to be a chronic
alcoholic, had had multiple previous admissions for treatment of
alcohol withdrawal. He smoked cigarettes and had mild chronic ob-
structive pulmonary disease. He was not taking medications.
Physical examination disclosed a slightly confused icteric man. Blood
pressure was 125/75 mm Hg recumbent and 120/70 mm Hg standing;
radial pulse was 84 beats/mm recumbent and 92 beats/mm standing; oral
temperature was 36.9°C; respirations were 14/mm. The sclerae and skin
were icteric, and bilateral Dupuytren's contractures were present; also
evident were multiple telangiectases over the upper trunk, neck, and
face and a caput medusae with reversal of flow in dilated superficial
abdominal wall veins. The patient had marked ascites and pitting edema
of the legs below the knees. He was slightly confused and was
disoriented as to time and place. A fine tremor of the outstretched
hands was present, and the patient had an unsteady gait; asterixis was
not present.
On admission laboratory data revealed a normal complete blood
count, prolonged prothrombin time, and a normal urinalysis. The serum
sodium was 133 mEq/liter; potassium, 3.7 mEq/liter; chloride, 97 mEq/
liter; bicarbonate, 25 mEq/liter: BUN, 2 mg/dl; creatinine, 0.8 mg/dl;
total bilirubin, 5.7 mg/dl; albumin, 2.1 g/dl; SGOT, 203 mU/mI; SGPT,
73 mU/mi; alkaline phosphatase, 480 mU/mi; and cholesterol, 112 mg/
dl. Radiographs of the chest and abdomen disclosed a normal heart,
normal lungs, an old fracture of the left ninth rib, and ascites; gallstones
were not seen. Ultrasound examination of the hepatobiliary system was
normal. A 20 ml diagnostic paracentesis revealed the ascitic fluid to be a
transudate without evidence of infection.
The patient was treated with a high-carbohydrate, low-protein, and
low-sodium diet, supplemented with multivitamins and low doses of
lactulose and chlordiazepoxide. Oral fluids were limited, and spirono-
lactone therapy was begun. Over the next week the patient remained
confused and lethargic; a CT scan of the head and a lumbar puncture
were normal. Insidious oliguria ensued. The body weight did not
change, and the serum creatinine concentration rose slowly to a zenith
of 7.0 mg/dl; serum bicarbonate concentration decreased to a nadir of 13
mEq/liter concurrent with an increase in the serum chloride concentra-
tion to a peak of 117 mEq/liter; serum sodium and potassium concentra-
tions remained relatively normal. Urine sodium concentrations, deter-
mined serially, were always less than 10 mEq/liter; the fractional
sodium excretion was uniformly less than 0.30% and urinary osmolality
was greater than 360 mOsm/kg H20. Cautious attempts were made at
combined intravascular volume expansion using albumin and diuretic
therapy using furosemide, with the patient under central cardiovascular
pressure monitoring (the basal mean pulmonary artery capillary wedge
pressure was 12 mm Hg); these attempts were to no avail. The patient
developed bilateral pneumonia with progressive hypoxemia, and he
died on the 21st hospital day. Autopsy disclosed severe alcoholic
cirrhosis with portal hypertension as manifested by ascites and spleno-
megaly. The kidneys were normal. The lungs showed bilateral pneumo-
nia due to Staphylococcus aureus and Escherichia coli.
Discussion
DR. GERALD F. DIBONA (Professor and Vice Chairman,
Department of Internal Medicine, University of Iowa College of
Medicine, and Chief, Medical Service, Veterans Administra-
tion Medical Center, Iowa City, Iowa): The clinical characteris-
tics of this patient's illness and hospital course fit the general
description of the hepatorenal syndrome. He had unexplained
progressive renal failure in the presence of hepatic disease;
neither clinical, laboratory, nor anatomic evidence of other
known causes of renal failure could be found [1, 2].
Strong circumstantial evidence indicates that the renal failure
in hepatorenal syndrome is functional in nature. Despite mark-
edly abnormal renal function, the histology of the kidney is
usually normal or only mildly abnormal, Tubular functional
integrity is well maintained, as reflected by persistent avid
sodium reabsorption and relatively unimpaired concentrating
ability. Direct evidence of the functional nature of the renal
failure is derived from the demonstration that kidneys trans-
planted from patients with the hepatorenal syndrome are capa-
ble of resuming normal function in recipients [3].
Patients with advanced cirrhosis of the liver often display a
characteristic circulatory disorder; these individuals tend to
develop arterial hypotension and to avidly retain sodium. Thus,
these patients generally manifest edema and ascites. These are
also the clinical characteristics of patients who develop the
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hepatorenal syndrome. In a recent review of abnormal volume
homeostasis in patients with cirrhosis, Better and Schrier
expressed the view that "patients with hepatorenal syndrome
merely represent the extreme spectrum of disturbance of vol-
ume control observed in all cirrhotic patients with ascites and
renal sodium retention [41." They reviewed the evidence in
support of the "underfilling" (a decrease in effective blood
volume with secondary renal sodium retention) and "overflow"
(primary renal sodium retention) theories of sodium retention
and ascites, and concluded that neither theory alone adequately
explains the findings in patients with cirrhosis. The authors
proposed that both underifiling and overflow are involved in
cirrhotic ascites. Alternately, each of the proposed mechanisms
might be more prominent at different stages in the course of the
disease [5]. Levy has postulated that the early phase of the
disease is characterized by primary sodium retention, which
progresses to ascites formation and a tendency toward arterial
hypovolemia that is related to alterations in the forces regulat-
ing transcapillary fluid partitioning, splanchnic venous pooling,
and peripheral vasodilation. The later phase of the disease
might be characterized by a decrease in effective blood volume
with secondary renal sodium retention. Although the role of
increased renal sympathetic nerve activity as an efferent arm of
the mechanism of renal sodium retention has been often dis-
cussed [21, Better and Schrier hypothesized that both the
overflow and underfilling theories involve specific stimuli that
elicit increased efferent renal sympathetic nerve activity
(ERSNA) which, in turn, plays a major role in the renal sodium
retention [4]. In recent years, a greater understanding of both
the nature and distribution of the intrinsic renal innervation and
the complexity of factors controlling ERSNA has led to a
burgeoning interest in the neural control of renal function [6].
Neural control of effective blood volume
According to the underfilling theory, a decrease in effective
blood volume is the stimulus that sets in motion a sequence of
events that tends to restore the effective blood volume to a
normal level. The concept of a neural mechanism controlling
blood volume parallels that of a classic neural reflex arc. That
is, the mechanism involves an afferent limb consisting of a
sensor that continuously monitors the blood volume, and an
afferent neural pathway that conveys information from the
sensor to an integrative site in the central nervous system.
From this integrative site emerges an efferent limb consisting of
neurohumoral pathways; stimuli from this limb influence the
function of effector organs that ultimately produce the appropri-
ate change in the blood volume.
This concept of neural volume control, first proposed by
Gauer and Henry [7], is presented in Figure 1. Their concept of
reflex volume regulation has three requirements: (1) a well-
defined compliance of the low-pressure vascular system relat-
ing intravascular volume to filling pressure; (2) appropriate
receptor (sensor) networks in the walls of the low-pressure
system that are responsive to changes in wall tension and that
discharge in appropriate areas of the central nervous system;
and (3) related efferent neurohumoral mechanisms that control
the major regulators of plasma volume: thirst, renal excretion of
water and sodium, and distribution of the extracellular fluid.
Several investigators have studied compliance (defined as the
quotient blood volume/central venous pressure x kg body
weight) and have identified a narrow and well-defined range of
effective vascular compliance and intrathoracic vascular com-
pliance in humans under various experimental conditions; the
values are 1.7 to 3.5 and 0.9 to 1.2 mllmm Hg/kg body weight,
respectively [reviewed in 7]. Because of the large differences in
the intrathoracic and extrathoracic blood volumes and the
relative similarity of their vascular compliances, the distensibil-
ity of the intrathoracic compartment must be much greater than
that of the extrathoracic compartment. Receptors in the walls of
the intrathoracic system are ideally suited for the detection of
changes in blood volume; the atria are the most distensible part
of this system. Mechanoreceptors (unencapsulated neural ele-
ments) are present in the wall of the left atrium; these discharge
with atrial filling and respond to changes in atrial transmural
pressure (Paintal type B receptor) [81. The mechanoreceptors
discharge into afferent myelinated fibers in the vagus nerve [9],
which have central representation in both the medulla [10] and
the supraoptic and paraventricular nuclei of the hypothalamus
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Fig. 1. Pathways for the regulation of
extracellular fluid, plasma, and blood volume
by a reflex mechanism involving the
autonomic nervous system.
Renal neural activity in hepatorenal syndrome 843
-tL•
100
Vagi intact Vagotomy
YY4J1IIi//
Fig. 2. Effect of left atrial balloon inflation on arterial pressure (AP),
left atrialpressure (LAP), the instantaneous frequency and integrated
voltage of efferent renal sympathetic nerve activity in anesthetized dogs
with vagi intact (left panel), and after bilateral cervical vagotomy (right
panel).
[11]. Thus, the left atrial mechanoreceptor fulfills the require-
ments for a sensor located in the low-pressure vascular system:
it possesses a well-defined compliance relating intrathoracic
volume to filling pressure, and it responds to changes in wall
tension (stretch) by discharging into afferent vagal fibers that
have appropriate central nervous system representation.
The related efferent neurohumoral effector mechanisms de-
pend on an integrated response of the central nervous system
centers. Left atrial mechanoreceptor stimulation (increases in
left atrial pressure due to blood volume expansion or left atrial
balloon inflation) produces four consequences: (1) It elicits
discharge of the supraoptic and paraventricular nuclei. These
same nuclei are also sensitive to osmotic stimuli, and they
provide a neurophysiologic basis for the interaction of volume
and osmotic stimuli, a mechanism that regulates release of
antidiuretic hormone [111. (2) It decreases arterial plasma
concentration of antidiuretic hormone [12]. (3) It alters sympa-
thetic outflow to the pre- and postcapillary peripheral resistance
vessels, a change resulting in an altered filtration pressure
which, in turn, favors the movement of fluid from blood to the
interstitial space [13]. (4) Finally, it decreases ERSNA [14, 15]
(Fig. 2).
When left atrial pressure is increased by left atrial balloon
inflation, arterial pressure decreases, partly because of obstruc-
tion of filling of the left ventricle and reduced cardiac output.
Ordinarily, a decrease in arterial pressure elicits a reflex
increase in ERSNA mediated by carotid and aortic barorecep-
tors. However, the abrupt and sustained decrease in ERSNA
reflects the dominant influence of the left atrial mechanorecep-
tors. After vagotomy, which interrupts the afferent limb of the
reflex arc, an increase in left atrial pressure and decrease in
arterial pressure are associated with an increase in ERSNA that
relationships, which correspond to the gain of the system, are
similar [161.
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Fig. 3. Effect of volume expansion (isotonic saline loading) and volume
depletion (furosemide administration) on the relationship between the
change in right a trial pressure (ARAP) and the change in renal nerve
activity (% RNA) in conscious rats. Gain = %ARNA/LRAP.
is derived from the carotid baroreceptor. The decrease in
ERSNA by left atrial mechanoreceptor stimulation is known to
be specific for the kidney because simultaneously measured
cardiac sympathetic nerve activity increases, and neither lum-
bar nor splenic sympathetic nerve activity change [14]. Using
differential cooling of the vagus and small left atrial balloons
which, on inflation, do not affect left ventricular filling or
arterial pressure, Linden, Mary, and Weatherill found the
decreased ERSNA response to depend on left atrial receptors
discharging into myelinated vagal afferent fibers [9]. Several
groups have demonstrated that expansion of blood volume
decreases, and depletion of blood volume increases, ERSNA in
animals in which carotid and aortic baroreceptor afferent input
is either eliminated or held constant, and that the changes in
ERSNA correlate inversely with the changes produced in left
atrial pressure [6]. Thus, left atrial mechanoreceptor stimula-
tion, as occurs with increases in left atrial pressure produced by
volume expansion, elicits an integrated neurohumoral response
consisting of a reduction in plasma concentration of antidiuretic
hormone, enhanced filtration of fluid from blood to the intersti-
tial fluid volume compartment, and a reduction in ERSNA.
In this context, the underfilling theory envisions a decrease in
effective blood volume, a corresponding decrease in left atrial
pressure, and an unloading of the left atrial mechanoreceptors.
Although there is some hysteresis, the left atrial mechanorecep-
tor mechanism operates in a bidirectional fashion: as might be
predicted from what I have just said, the integrated neuro-
humoral response to reduced left atrial pressure consists of an
increase in plasma concentration of antidiuretic hormone, de-
creased filtration of fluid from blood to the interstitial fluid
volume compartment, and an increase in ERSNA. In studies
using renal nerve recording techniques in conscious, freely
moving rats, we demonstrated that volume expansion both
increases right atrial pressure, which in rats closely correlates
with left atrial pressure, and decreases ERSNA, whereas
volume depletion with furosemide decreases right atrial pres-
sure and increases ERSNA (Fig. 3); the slopes of the two
1 mm
Furosemide volume depletion (8)
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Disturbances of neural control of effective
blood volume in cirrhosis
According to the overflow theory as applied to patients with
cirrhosis, the stimulus for increased ERSNA is an increase in
intrahepatic sinusoidal pressure [4]. This suggestion is based on
the observation that renal sodium retention and ascites forma-
tion are abolished and normal mineralocorticoid escape is
restored in experimental biliary cirrhosis when the elevated
intrahepatic sinusoidal pressure characteristic of this condition
is relieved by a side-to-side portacaval shunt [171. Other work-
ers have studied the effect on renal function of alterations in
pressure within various segments of the hepatic portal circula-
tion. Haberich and coworkers observed a rapid reduction in
urine flow following either brief or prolonged increases in portal
vein pressure in the rat; conversely, decreasing portal vein
pressure produced an increase in urine flow [18, 19]. They
produced changes in portal vein pressure using an inflatable cuff
to occlude the main portal vein. Liang showed that increases in
portal vein pressure of less than 15 cm H20, produced by
occluding the main hepatic portal vein in the dog, increased
urinary flow rate and chloride excretion as well as renal plasma
flow and glomerular filtration rate [20], Occluding the main
hepatic portal vein would tend to decrease intrahepatic sinusoi-
dal pressure. These responses were reversibly abolished by
application of local anesthetics to the renal neurovascular
pedicle but not by vagotomy. This study suggests that increas-
ing portal vein pressure without increasing intrahepatic sinusoi-
dal pressure decreases ERSNA. In confirmation of this view,
Niijima observed that 5-minute periods of main portal vein
occlusion in the rabbit produced decreases in mean arterial
pressure and ERSNA that were unaffected by vagotomy [21].
We showed that main portal vein occlusion in the dog produced
a 40% decrease in ERSNA, from 9,8 0.5 to 7.4 0.4 Hz, as
well as a slight reduction in mean arterial pressure (Fig. 4).
Again, these decreases in ERSNA occurred with decreases in
mean arterial pressure that ordinarily would lead to sinoaortic
baroreceptor-mediated increases in ERSNA.
In contrast to these results, Anderson et al showed that acute
increases in portal vein pressure produced by partial main
portal vein occlusion in dogs decreases cardiac output and
mean arterial pressure [22]. Further, despite a constant renal
arterial pressure, they found that renal blood flow, glomerular
filtration rate, urinary solute excretion, and free-water clear-
ance also decreased; renal vascular resistance and renin secre-
tion increased. Renal denervation prevented decreases in renal
blood flow, glomerular filtration rate, and urinary solute excre-
tion as well as increases in renal vascular resistance and renin
secretion rate, but it did not prevent antidiuresis. The investiga-
tors considered these observations to be compatible with a
splanchnorenal neural reflex. To exclude the possibility that the
renal responses were related to the decreases in mean arterial
pressure and cardiac output, they partially occluded the thorac-
ic inferior vena cava (TIVC) in an additional group of dogs, thus
producing reductions in mean arterial pressure and cardiac
output similar to those occurring with main portal vein occlu-
sion. Although they observed no changes in renal blood flow,
glomerular filtration rate, and renal vascular resistance at
constant renal arterial pressure, the level of portal venous
pressure achieved with partial TIVC occlusion (9 mm Hg) was
much less than that achieved with main portal vein occlusion
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(20 mm Hg). Unfortunately, data on left atrial pressure, the
stimulus for the left atrial mechanoreceptors that are known to
be a critical determinant of ERSNA, were not presented for
either intervention. Decreases in urinary solute excretion and
free-water clearance also were found with partial TIVC occlu-
sion; we previously showed that these decreases depend on
intact renal innervation [23]. In contrast to the previously
mentioned studies by Liang [201 and Niijima [21], work by
Anderson and colleagues suggests that an increase in portal
vein pressure produces increases in ERSNA, even though data
on renal nerve recordings were not presented [22].
Subsequent clarification of these conflicting results was de-
rived from neurophysiologic studies. Niijima studied afferent
hepatic nerve activity in the isolated perfused guinea pig liver
and the rabbit liver in vivo [24]. He increased the perfusion
pressure in the portal vein of the isolated guinea pig liver and
raised the portal venous pressure by intravenous fluid injection
in the rabbit in vivo. Both maneuvers, which probably in-
creased intrahepatic sinusoidal pressure, increased afferent
hepatic nerve activity. Increasing hepatic arterial pressure was
without affect. Studies by Kostreva, Castaner, and Kampine in
dogs provide the strongest evidence for a hepatorenal neural
reflex arc, however [25]. Inferior vena cava occlusion at the
diaphragm increased hepatic and portal venous pressure by
about 5 to 30 mm Hg without affecting mean arterial pressure;
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Fig. 4. Effect of main portal vein occlusion on mean arterial pressure
and integrated voltage of efferent renal sympathetic nerve activity in
anesthetized dogs.
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the occlusion also increased both hepatic afferent nerve activity
and ERSNA. Hepatic nerve section prior to inferior vena cava
occlusion abolished the increase in ERSNA. Neither carotid
sinus denervation, bilateral vagotomy, nor phrenectomy pro-
duced an effect on the ERSNA response to inferior vena cava
occlusion. Main portal vein occlusion, which increased portal
venous but not hepatic venous pressure, either did not increase
or slightly decreased ERSNA. Inferior vena cava occlusion at
the diaphragm also increased cardiopulmonary sympathetic
nerve activity (measured in ansa subclavia), but this maneuver
was not associated with a change in heart rate or arterial
pressure; hepatic nerve section reduced but did not abolish this
response. This study localized the site of mechanoreceptors
involved in a hepatorenal reflex arc to an intrahepatic sinusoidal
site. This reflex arc is stimulated by increased intrahepatic
sinusoidal pressure. Although increased portal venous pressure
by itself decreases ERSNA, the combination of increased
hepatic venous, portal venous and, therefore, intrahepatic
sinusoidal pressure increases ERSNA. These observations fur-
ther underscore the dominance of the intrahepatic sinusoidal
pressure in an assessment of the effects of alterations in
pressure in the hepatic portal circulation on ERSNA.
Patients with cirrhosis who have renal sodium retention,
edema, and ascites uniformly manifest portal hypertension.
Portal hypertension is defined as a direct portal vein pressure or
wedged hepatic vein pressure of more than 5 mm Hg greater
than the inferior vena cava pressure; we will infer that portal
hypertension reflects increased intrahepatic sinusoidal pressure
[26]. In patients with alcoholic cirrhosis, direct measurement of
portal vein pressure correlates extremely well (r = 0.96, N =
29) with simultaneously determined wedged hepatic vein pres-
sure over a range of 0 to 30mm Hg [26]; these levels are similar
to those shown by Kostreva et alto increase ERSNA [25].
Thus, in the presence of portal hypertension, one finds all the
elements of a classic hepatorenal neural reflex arc (Fig. 5): an
afferent limb consisting of intrahepatic baroreceptors that re-
spond to an increase in intrahepatic sinusoidal pressure by
eliciting increased afferent hepatic nerve activity, and an effer-
ent limb consisting of increased ERSNA. Thus, with both the
underfilling and overflow theories, neural reflex mechanisms
elicit increases in ERSNA (Fig. 6), which serves as an effector
pathway capable of influencing renal function.
Effects of ERSNA on renal function
The effects of the renal nerves on renal function are multiple
and complex [6]. The intrinsic renal innervation is exclusively
noradrenergic and involves the afferent and efferent arterioles,
juxtaglomerular apparatus, proximal and distal convoluted tu-
bules, and thick ascending limb of Henle's loop. Increases in
ERSNA produce renal vasoconstriction; neither physiologic
nor anatomic evidence supports the existence of sympathetic
cholinergic vasodilator fibers in the kidney. Direct electrical
stimulation of the efferent renal nerves produces frequency-
dependent decreases in renal blood flow and glomerular filtra-
tion rate that are abolished by renal alpha-adrenoreceptor
(alpha-i) or adrenergic blockade.
Direct as well as reflex alterations in ERSNA produce
reciprocal changes in urinary sodium and water excretion
without eliciting changes in glomerular filtration rate, renal
blood flow, or intrarenal distribution of blood flow. This direct
neural effect on renal tubular sodium reabsorption occurs in the
proximal convoluted tubules, the thick ascending limb of the
loop of Henle, and in the more distal nephron segments.
Although increases in ERSNA are known to increase the renal
secretion of renin and prostaglandins, the neural effect on renal
tubular sodium reabsorption does not depend on the intermedi-
ate action of angiotensin II or prostaglandins [6]. Using a
variety of alpha- and beta-adrenoreceptor antagonists, we have
shown that the antinatriuretic response to renal nerve stimula-
tion is mediated by renal alpha-i adrenoreceptors, but that renal
alpha-2, beta-I, and beta-2 adrenoreceptors are not involved
[27]. Conversely, the renin secretory response to renal nerve
stimulation is mediated by renal beta-l adrenoreceptors; neither
renal beta-2, alpha-l, nor alpha-2 adrenoreceptors (inhibitory or
stimulatory) are involved [27].
The vital role of the efferent renal sympathetic nerves in the
regulation of renal sodium handling is best shown in studies in
unanesthetized animals and humans. Gill and Bartter demon-
strated that normal subjects with autonomic insufficiency pro-
duced by guanethidine administration were unable to lower
urinary sodium excretion sufficiently to avoid negative external
sodium balance in response to a reduction in dietary sodium
intake, despite decreases in glomerular filtration rate [28].
Patients with the Shy-Drager form of idiopathic autonomic
CNS/Soinal cord
Afferent
limb
Fig. 5. Pathways involved in the hepatorenal reflex.
+ Efferent renal
sympathetic nerve
Efferent activity
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insufficiency have a similar defect, even if they are receiving
mineralocorticoid hormone [291. Chronic bilateral renal dener-
vation or systemic sympathetic blockade with reserpine or
guanethidine renders conscious rabbits [30] and dogs [311
unable to reduce urinary sodium excretion sufficiently to avoid
negative external sodium balance when challenged with a
reduction in dietary sodium intake. We demonstrated that renal
denervation renders the conscious rat unable to maintain exter-
nal sodium balance when dietary sodium intake is restricted;
negative external sodium balance occurred [32]. Thus, the
efferent renal sympathetic nerves are an important component
of the body's defense against sodium losses and therefore
extracellular fluid volume depletion.
Evidence for increased ERSNA in cirrhosis
What evidence supports increased efferent renal sympathetic
nerve activity in human subjects with hepatic cirrhosis, edema,
and ascites? In cirrhotic patients with marked reduction in the
renal clearance of para-aminohippurate (PAH) and inulin, intra-
venous administration of 50 g of albumin had little effect on the
renal clearances of those substances [331. However, the prior
administration of albumin prevented a fall in mean arterial
pressure when phenoxybenzamine, an alpha-adrenoreceptor
antagonist, was subsequently administered intravenously;
phenoxybenzamine increased the renal clearance of PAH more
than twofold [331. Epstein and coworkers noted that intrarenal
infusion of phentolamine, an alpha-adrenoreceptor antagonist,
did not increase renal blood flow (measured via the radioactive
xenon washout technique) in cirrhotic patients [34]. But the
majority of patients experienced significant reductions in arteri-
al pressure that could have masked phentolamine-induced
increases in renal blood flow. Henriksen and colleagues demon-
strated that the concentration of norepinephrine in renal vein
blood (mean, 0.79 ng/ml) exceeded that in simultaneously
obtained arterial boood (mean, 0.59 ng/ml) in all 5 cirrhotic
patients examined; no difference in epinephrine concentrations
was observed [35]. In a subsequent report from the same
laboratory, Ring-Larsen and associates reported that the con-
centration of norepinephrine in renal vein blood (mean SE,
0.63 0.11 ng/ml) exceeded that in simultaneously obtained
arterial blood (0,47 0.09 nglml) in all 10 cirrhotic patients
examined [36]. In addition, these studies demonstrated that
peripheral plasma norepinephrine concentrations were higher in
cirrhotic patients than in control subjects, and that this increase
was not due to decreased hepatic extraction. The increased
peripheral plasma norepinephrine concentrations correlated
positively with measurements of wedged hepatic vein pressure(r =
—0.86) and correlated negatively with measurements of
plasma volume (r = —0.83); these results support both the
overflow and underfilling theories.
Using the radioactive xenon washout technique, Ring-Larsen
and associates showed that basal renal blood flow was lower,
and renal vascular resistance higher, in cirrhotic patients than in
control subjects [36]. During a 60° head-up tilt, renal vascular
resistance and peripheral plasma norepinephrine concentration
increased in parallel in the cirrhotic and control subjects [36].
The assessment of increased systemic or regional sympathoad-
renergic activity is difficult when based on measurements of
peripheral plasma norepinephrine concentrations alone [37—39],
but considerable data are available to permit a reasonably
accurate prediction of ERSNA from renal venoarterial plasma
norepinephrine concentration differences or secretion rates.
When ERSNA is zero in the denervated kidney, the concentra-
tion difference has a negative value; the plasma norepinephrine
concentration in the renal vein blood is less than that in arterial
blood [40]. In the nonstimulated, innervated kidney (that is,
with basal prevailing ERSNA) in the dog [41, 42] and human
[43], the renal vein plasma norepinephrine concentration is the
same as, or only slightly greater than, that in arterial blood.
With graded electrical stimulation of the renal nerves over the
frequency range of 0.5 to 18 Hz, however, both the renal
venoarterial plasma norepinephrine concentration difference
and the renal norepinephrine secretion rate increase in a
frequency-dependent fashion [40, 41]. Similar findings have
been observed with haroreflex alterations in ERSNA in the rat
[44]. Thus, the consistently increased norepinephrine concen-
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theory (right-hand portion) and the overflow
theory (left-hand portion) can account for an
increase in efferent renal sympathetic nerve
activity.
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tration difference between the renal vein and artery supports
the view that ERSNA is increased in patients with cirrhosis
complicated by ascites and edema. Further support for this
view comes from recent studies by Esler who, using radioiso-
tope methods, showed that both total norepinephrine release to
plasma (1141 249 ng!min vs. 399 33 ng!min) and renal
norepinephrine release (305 125 nglmin vs. 77 13 ng/min)
were increased in decompensated cirrhotic patients as com-
pared to healthy volunteers [45].
Studies by Gatta and colleagues provide further evidence of
increased ERSNA causing renal vasoconstriction in patients
with liver cirrhosis and portal hypertension [46]. Measuring
renal blood flow with the radioactive xenon washout technique,
these investigators showed that an injection of dihydroergocris-
tine, an alpha-adrenoreceptor antagonist, into the renal artery
increased mean renal blood flow from 1.52 0.30 to 1.73 0.32
mI/min/g (normal value in 14 control subjects, 4.53 0.97 ml!
min/g) without altering arterial pressure. Thus, administration
of an aipha-adrenoreceptor antagonist into the renal artery
increased renal blood flow and decreased renal vascular resist-
ance; that is, it produced renal vasodilation. These were acute
studies and only small, insignificant increases in urinary flow
rate and sodium and chloride excretion were observed, possibly
because of a 13% decrease in inulin clearance.
Similar observations supporting the view that an increased
ERSNA contributes to the renal vasoconstriction of decompen-
sated liver cirrhosis were made by Ring-Larsen, Henriksen, and
Christensen [47]. Six control subjects had mean renal blood
flow (measured by the radioactive xenon washout technique)
greater than 3.0 ml/min/g and peripheral plasma norepinephrine
concentrations less than 0.3 ng!ml, whereas 24 patients with
cirrhosis, ascites, and edema had values for mean renal blood
flow between 1.0 and 3.0 ml!min!g and peripheral plasma
norepinephrine concentrations between 0.2 and 2.0 ng/ml. The
level of mean renal blood flow correlated inversely with the
peripheral plasma norepinephrine concentration in the patients
with decompensated cirrhosis whether or not the data on the
control subjects were included. Bichet, Van Putten, and Schrier
studied the response to an acute oral water load in 26 patients
with decompensated liver cirrhosis and found a higher peripher-
al plasma norepinephrine concentration in the patients who
excreted the water load abnormally than in those who excreted
the load normally [48]. The authors noted (1) a positive correla-
tion between plasma levels of norepinephrine and arginine
vasopressin after the water load; (2) a negative correlation
between plasma norepinephrine and the percentage of the water
load excreted; (3) a positive correlation between plasma norepi-
nephrine and both plasma renin activity and plasma aldoster-
one; (4) a negative correlation between plasma norepinephrine
and urinary sodium excretion after the water load. The authors
interpreted these data as indicating that increased sympathetic
efferent discharge, based on the underfilling theory and reflect-
ed by peripheral plasma norepinephrine concentration, corre-
lates closely with sodium and water retention in patients with
decompensated liver cirrhosis, and that this increase might be
of pathogenetic significance.
To study the effect of increased ERSNA on renal sodium
retention, investigators have taken advantage of the technique
of head-out water immersion as a physiologic state in which
blood volume is redistributed and central blood volume is
persistently increased [49]. The natriuretic and kaliuretic re-
sponse is similar in the immersed individual to that observed
after administration of an isotonic saline load of 2 liters over 2
hours. Water immersion provides a unique opportunity for
testing the underfilling theory because it increases effective
blood volume in the central or intrathoracic compartment
without increasing total blood volume by potentially hazardous
fluid administration, and it would be expected to be sensed by
the left atrial mechanoreceptor as an increase in left atrial
pressure [49].
Patients with decompensated liver cirrhosis have been sub-
jected to head-out water immersion [50]. Striking natriuresis
and kaliuresis result, often greater than that in control subjects;
these alterations are independent of changes in the renin-
angiotensin-aldosterone system and are accompanied by in-
creases in urinary excretion of prostaglandin E2. Because the
usual antinatriuresis of the cirrhotic patient was reversed by a
maneuver that redistributes blood volume without increasing
total blood volume, these studies strongly support the concept
that a decreased effective blood volume (a central tenet of the
underfilling theory) is an important determinant of the avid
renal sodium retention in patients with decompensated cirrho-
sis. In 8 patients with decompensated liver cirrhosis, Bichet,
Groves, and Schrier showed that head-out water immersion
increased cardiac index, right atrial pressure, and pulmonary
capillary wedge pressure [51]. The peripheral plasma concen-
trations of renin, arginine vasopressin, aldosterone, and norepi-
nephrine all were significantly decreased by immersion, and the
patient's ability to excrete water and sodium after an acute oral
water load improved significantly. The increase in right atrial
pressure correlated positively with both the increase in the
percentage of water load excreted (negatively correlated with
the decrease in arginine vasopressin levels) and the increase in
fractional sodium excretion. The decrease in plasma norepi-
nephrine concentration produced by head-out water immersion
was correlated with the concurrent increase in right atrial
pressure. There was an inverse correlation between plasma
norepinephrine concentration and fractional sodium excretion.
Thus, if one assumes that the increase in right atrial pressure is
associated with a directionally similar change in left atrial
pressure, the increased central blood volume induced by im-
mersion might stimulate left atrial mechanoreceptors and pro-
duce decreases in arginine vasopressin and ERSNA. The
decrease in ERSNA in turn could contribute to reductions in
plasma concentrations of renin, aldosterone, and norepineph-
rifle. The net result would be an increase in the kidney's ability
to excrete a sodium and water load.
Epstein performed similar studies of water immersion in 15
patients with decompensated cirrhosis and found that whereas
13 of the 15 patients had a natriuresis, only 6 of the 15 had a
suppression of the elevated peripheral plasma norepinephrine
concentration [52]. Neither the peak diuretic nor the peak
natriuretic response to immersion correlated with basal plasma
norepinephrine concentration or with the extent of suppression
of plasma norepinephrine concentration. Because of the rela-
tive fallibility of assessing ERSNA from measurements of
peripheral plasma norepinephrine concentration [37—39], mea-
surement of the renal venoarterial plasma norepinephrine con-
centration difference during water immersion will be needed to
define more precisely the role of increased ERSNA in the renal
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sodium and water retention of decompensated cirrhosis.
The role of the renal nerves in the renal sodium retention of
cirrhosis has been studied in several experimental models. In
acute experiments, the antinatriuretic response to a hepatic
venous outflow block (produced by infusion of histamine into
the portal vein) was not affected by renal denervation [531.
Using the model of biliary cirrhosis produced by chronic
ligation of the bile duct, Chaimovitz and colleagues reported
that neither acute unilateral surgical denervation of the kidney
nor renal arterial infusion of phenoxybenzamine altered urinary
sodium excretion in anesthetized dogs [54]. It is unclear,
however, whether these animals had developed ascites or even
renal sodium retention, as their fractional sodium excretion
ranged from 0.12% to 0.24%, as compared to an average of
0.34% in similarly prepared normal control animals. Further-
more, in dogs with common bile duct ligations, the interven-
tions did produce significant increments in urinary sodium
excretion in the experimental kidneys as compared to the
contralateral control kidneys but the urinary sodium excretion
responses were not greater than those in the normal control
animals. The animals might have been studied too early, prior
to activation of the neural reflex arcs that could lead to ERSNA
as a mediator of renal sodium retention. Alternately, the
experimental model of biliary cirrhosis might not be accompa-
nied by so marked a tendency to renal sodium retention. In
support of the view that experimental biliary cirrhosis may not
be representative of other forms of cirrhosis, Chaimovitz and
colleagues assessed the natriuretic and diuretic responses to
extracellular fluid volume expansion in patients with primary
biliary cirrhosis; they demonstrated that both the diuretic and
natriuretic responses were greater than those observed in
normal volunteers and edema-free patients with alcoholic cir-
rhosis [55].
Patho genesis of the hepatorenal syndrome
The hepatorenal syndrome can be defined as renal failure in
patients with liver disease in the absence of clinical, laboratory,
or anatomic evidence of other known causes of renal failure [2].
The clinical diagnostic criteria can be considered in two catego-
ries, general and renal. The general criteria are: (1) presence of
liver disease; (2) absence of primary renal disease or other
known causes of renal failure; (3) acute or subacute onset of
progressive renal functional impairment; and (4) no sustained
improvement with expansion of effective blood volume [2]. The
renal functional criteria are: (1) reduced glomerular filtration
rate; (2) urine sodium concentration less than 10 mEqlliter; (3)
fractional sodium excretion less than 1%; and (4) ratio of urine
to plasma osmolality (U/Posm) greater than 1 [2].
No known clinical, functional, or laboratory characteristics
(or combination thereof) identify the patients with decompen-
sated cirrhosis who will develop the hepatorenal syndrome. As
summarized by Papper, the largest body of evidence still
supports the view that a renal circulatory mechanism is the root
cause of the hepatorenal syndrome [2]. The combination of
reduced glomerular filtration rate, concentrated urine, and very
low urinary sodium concentration is characteristic of a reduc-
tion in renal perfusion, and, in fact, measured renal blood flow
is reduced [56, 57]. The slight reduction in mean arterial
pressure that is characteristically present and the frequency
with which the onset of renal failure follows clinical events that
reduce effective blood volume (gastrointestinal bleeding, para-
centesis, diuresis) support the importance of an alteration in the
renal circulation. Attempts to restore effective blood volume
and renal perfusion may improve renal function transiently [56].
The relative renal cortical ischemia and unstable renal arterial
circulation (afferent renal arterial vasoconstriction) are evi-
dence for abnormal renal circulation in humans with hepatore-
nal syndrome [34].
Kidneys from patients with the hepatorenal syndrome func-
tion normally in the presence of a normal liver. Relieving the
kidney of the burden of an abnormal liver has been accom-
plished both by successfully transplanting the kidney from a
patient with the hepatorenal syndrome into a noncirrhotic
recipient [3] and by transplanting a normal liver into a patient
with the hepatorenal syndrome [58]. These findings prove that
the renal failure in hepatorenal syndrome is functional in
nature, representing a response to extrarenal influences rather
than an intrinsic renal disorder.
The extrarenal circulation of patients with the hepatorenal
syndrome is also abnormal. Although cardiac output and plas-
ma volume are variably affected, cerebral and hepatic blood
flow, like renal blood flow, are reduced [59, 60]. When cardiac
output is elevated, peripheral vasodilation occurs, with arterio-
venous shunting of blood in muscles, lung, and possibly in the
kidney and liver [61].
The observations that the renal failure of hepatorenal syn-
drome is functional and, under certain circumstances, revers-
ible and that it occurs in the setting of an abnormal renal and
extrarenal circulation suggests that the abnormal renal circula-
tion represents the kidney's physiologic response to alterations
in the extrarenal circulation. In keeping with this view, both the
underfilling and overflow theories predict disturbances in the
neural control of effective blood volume and in the extrarenal
circulation; these disturbances elicit increases in ERSNA that
are capable of causing the abnormalities found in the renal
circulation: afferent renal arterial vasoconstriction, relative
renal cortical ischemia, and unstable renal arterial circulation.
Furthermore, as cited earlier, there is increasing evidence for
increased ERSNA in decompensated cirrhotic patients.
An alternate view is that a humoral or neurohumoral agent,
produced or inadequately inactivated by the diseased liver or
shunted away from the liver via portal-systemic anastomoses, is
responsible for both the abnormal renal and extrarenal circula-
tion. Many humoral agents have been considered: vasodilator
material, jaundiced serum, false neurotransmitters, endotoxins,
renin-angiotensin, prostaglandins, vasoactive intestinal poly-
peptide, and kallikrein-kinin. Although improvements in renal
function in the hepatorenal syndrome correlated with decreases
in peripheral plasma renin activity following peritoneovenous
shunting [62], saralasin, a competitive antagonist of angiotensin
II, failed to improve renal function in patients with hepatorenal
syndrome [63].
As recently summarized by Epstein and Lifschitz [64], some
diseases are characterized by decreased effective blood volume
and avid renal sodium retention; decompensated cirrhosis
clearly falls in this category [65). Administration of prostaglan-
din synthesis inhibitors to patients with such a disease can elicit
marked reduction in glomerular filtration rate and thus produce
acute renal failure. Studying dogs with experimental biliary
cirrhosis and ascites produced by common bile duct ligation,
Fig. 7. Pathways contributing to the
pathogenesis of the hepatorenal syndrome.
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Zambraski and Dunn found that indomethacin produced
marked renal vasoconstriction and decreased glomerular filtra-
tion rate [661. Thus, heightened renal prostaglandin synthesis
might be an important renal adaptive mechanism in states of
reduced effective blood volume, and defects in this response
could contribute to the renal hemodynamic abnormalities ob-
served in the hepatorenal syndrome. Additionally, decreased
plasma concentration of prekallikrein and bradykinin, peptides
with renal vasodilatory capacity, have been observed in the
hepatorenal syndrome [67].
Of more recent interest is the discovery of an atrial natriuretic
factor, a small-molecular-weight peptide derived from specific
granules within atrial but not ventricular muscle cells [681. This
factor possesses diuretic and natriuretic properties but does not
inhibit sodium-potassium ATPase activity nor does it cross-
react with digoxin antibody. Mechanisms governing its release
are not clearly known, but it might be regulated by alterations in
left atrial pressure that reflect changes in blood volume (the
underfilling theory) or by reflex alterations in cardiopulmonary
sympathetic nerve activity that reflect intrahepatic mechanore-
ceptor stimulation (the overflow theory). Whether decreased
circulating levels of atrial natriuretic factor also contribute to
the renal sodium retention of decompensated cirrhosis is not
known. A detailed review of the available information conclud-
ed that there is insufficient evidence supporting the view that a
humoral agent is solely responsible for both the abnormal renal
and extrarenal circulation in the hepatorenal syndrome [2].
In the overall pathogenesis of the hepatorenal syndrome, it is
my view that increased ERSNA interacts with a variety of
hemodynamic and humoral abnormalities to produce the renal
failure (Fig. 7). But because increased ERSNA alone can
directly elicit virtually all the postulated hemodynamic, humor-
al, and tubular mechanisms proposed to explain the clinical
manifestations of the hepatorenal syndrome, it seems reason-
able to place primary emphasis on this phenomenon.
In evaluating a patient suspected of having the hepatorenal
syndrome, it is essential that one exclude the presence of
volume depletion. A sustained improvement (for example,
diuresis and increase in glomerular filtration rate) with expan-
sion of effective blood volume would be evidence against
hepatorenal syndrome and in favor of reversible (prerenal)
azotemia and oliguria secondary to decreased effective blood
volume. When volume repletion does not produce improvement
in renal function, and when other known causes of renal failure
are absent, the diagnosis of hepatorenal syndrome becomes
more secure.
The treatment of established hepatorenal syndrome is gener-
ally unsatisfactory [2]. The introduction of a peritoneovenous
(La Veen) shunt for the continuous return of ascitic fluid to the
circulation has an uncertain role clinically but has provided
additional insight into the pathogenesis of the hepatorenal
syndrome. Some [69—70] but not all [71] investigators have
observed a decrease in intrahepatic sinusoidal pressure follow-
ing peritoneovenous shunting, as reflected by measurements of
wedged hepatic vein pressure. In patients with well-docu-
mented hepatorenal syndrome, insertion of peritoneovenous
shunt or construction of a side-to-side portacaval shunt can
result in significant increases in glomerular filtration rate and
plasma volume with spontaneous diuresis and natriuresis [62,
72]. That these two dissimilar procedures appear to have a
common effect suggests that both translocate fluid from the
splanchnic area to the venous circulation and preferentially
expand the central blood volume compartment. Nevertheless,
the peritoneovenous shunt cannot be recommended in the
routine management of cirrhotic patients with ascites or the
hepatorenal syndrome until unambiguous demonstration of its
therapeutic efficacy is available from randomized, prospective
clinical trials [73, 74].
Questions and answers
DR. SERAFINO GARELLA (Renal Division, Michael Reese
Hospital): How do you relate your thesis concerning sodium
retention to the fall in GFR that is such an important part of the
hepatorenal syndrome?
DR. DIB0NA: It would be reasonable to conjecture that the
renal insufficiency is related to sustained and progressively
intense renal nerve stimulation. I rather think that it is not the
sole factor and that there must be a concomitant failure of
previously effective compensatory mechanisms. For example,
we know of the deleterious effect on GFR when indomethacin
+ Efferent Renal Sympathetic Nerve Activity
RBF + GFR -i-————- + Renin — Angiotensin .- + Tubular Na + H20 reabsorption
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or other prostaglandin synthesis inhibitors are administered to
cirrhotic patients who have sodium retention and edema forma-
tion [64—66]. It is reasoned that renal prostaglandin synthesis
increases as a compensatory mechanism to maintain GFR and
renal blood flow and to oppose the collective influence of
several renal vasoconstrictor stimuli (for example, nerve activi-
ty, angiotensin II). In the hepatorenal syndrome, the precise
nature of the compensatory mechanisms and the reasons for
their eventual failure are unknown.
DR. FREDRIC COE (Renal Section, Billings Hospital): It
seems from what you have said that prazosin and propranolol
given together ought to be extremely effective in treating
cirrhotic patients who have low GFRs and sodium retention.
Has this combination been tried?
DR. DIB0NA: I do not know the results of combined prazosin
and propranolol administration to such cirrhotic patients. An
important issue would be the avoidance of a substantial reduc-
tion in arterial pressure that might attenuate any natriuretic
responses to the combined therapy.
DR. C0E: Do you think the hepatic mechanoreceptor mecha-
nism plays a role in the very marked sodium and water retention
that occurs in congestive heart failure with passive congestion
of the liver?
DR. DIB0NA: It is possible that congestive heart failure with
passive hepatic congestion would increase intrahepatic sinusoi-
dal pressure sufficiently, as with constriction of the thoracic
inferior vena cava above the diaphragm [25], and lead to a
similar reflex increase in efferent renal sympathetic nerve
activity.
DR. JORDAN J. COHEN: Data from water immersion studies
indicate that a prompt increase in hemodynamics leads to a
natriuresis in patients with cirrhosis. This observation puzzles
me. It would seem to suggest that the underlying sodium-
retaining mechanism can be overridden by volume expansion
and that the potential exists for "escape" from the sodium-
retaining effects of the renal nerve stimulation, Why doesn't
that happen spontaneously? If renal nerve stimulation promotes
sodium retention, why doesn't it expand intravascular volume
and eventually produce the kind of effect that water immersion
does?
DR. DIB0NA: The answer may lie in differences in kinetics
and time course. Head-out water immersion produces an acute,
substantial and preferential increase in intrathoracic (central)
blood volume. The renal sodium retention from chronic renal
nerve stimulation is slower, probably smaller on a daily basis,
and is more generally distributed in accord with the forces
governing the abnormal blood volume distribution in cirrhosis.
Therefore, it is possible that the renal sodium retention due to
chronic renal nerve stimulation might not produce the same
stimulus, in terms of intrathoracic blood volume expansion, as
does head-out water immersion.
DR. GARY TOBACK (Renal Section, Billings Hospital): Some
believe that the bile acids that accumulate in the plasma in
patients with end-stage liver disease, especially in the presence
of renal ischemia, might affect the kidney by diminishing renal
hemodynamics. Is this an important factor?
DR. DIBONA: Perfusion of an isolated rabbit kidney with
plasma taken from baboons with surgically induced obstructive
jaundice increases the renal vasoconstrictor response to norepi-
nephrine [75]. In rats with only unconjugated hyperbil-
irubinemia, no difference was found in the incidence of ische-
mia-induced renal impairment between animals with and those
without bile duct ligation [76], whereas rats with bile duct
ligation and conjugated hyperbilirubinemia had an increased
incidence of renal failure [77]. These findings suggest that
increased levels of conjugated bilirubin render the kidney more
susceptible to ischemia. However, clinical observations indi-
cate that the hepatorenal syndrome can develop while jaundice
is decreasing or in the presence of minimal jaundice [2].
DR. TOBACK: The data you presented indicate that volume
expansion leads to an increase in sodium clearance in patients
with biliary cirrhosis (compared to controls), whereas in Laen-
nec's cirrhosis sodium clearance is reduced. Does this imply
that different types of cirrhosis result in different mechanisms
for renal sodium retention?
DR. DIBONA: Portal hypertension (increased intrahepatic
sinusoidal pressure) is related to nodular regeneration in the
liver and to cirrhosis. Nodular regeneration is generally consid-
ered a late feature of primary biliary cirrhosis; it is therefore
possible that the development of increased intrahepatic sinusoi-
dal pressure as the initial step in both the underfilling and
overflow theories is more gradual in primary biliary cirrhosis
than in Laennec's cirrhosis. This could account for some of the
differences observed in renal sodium handling.
DR. DAVID BUSHINSKY (Renal Section, Billings Hospital):
Another therapeutic approach suggested by your thesis would
be to infuse a pressor agent such as dopamine to increase renal
blood flow and then produce neuronal blockade with an agent
such as guanethidine. Given the fact that the hepatorenal
syndrome is associated with virtually a 100% mortality rate,
would such an approach be reasonable?
DR. DIBONA: One would anticipate that an improvement in
renal perfusion coupled with a reduction in the postulated
increased level of renal nerve activity would be beneficial. Two
groups of workers have used octapressin to increase renal blood
flow and decrease renal vascular resistance in cirrhotic patients
[78, 79]. In considering such therapy, it is important that one
avoid maneuvers that would decrease renal arterial pressure
and thus attenuate any beneficial effects derived from improved
renal perfusion.
DR. COHEN: Do we know how renal nerve stimulation
actually translates into increased tubular sodium transport?
What is the molecular basis for the effect?
DR. DIBONA: The neurotransmitter released from renal nerve
terminals, norepinephrine, stimulates Na-K-ATPase; it pro-
duces this effect by counteracting the inhibitory effect of
endogenous vanadate on the enzyme [80, 81]. Therefore in-
creased norepinephrine release during renal nerve stimulation
would increase the activity of the Na-K-ATPase pump at the
basolateral membrane of the renal tubular epithelial cell.
DR. SATISH KATHPALIA (Renal Division, Michael Reese
Hospital): Do kidneys transplanted from cirrhotic patients
begin to function because of denervation?
DR. DIBONA: The evidence would indicate that the abnormal
renal function is reversed by changing the hepatic environment,
either by transplanting the kidney into a recipient with a normal
liver [3] or by transplanting a normal liver into the patient [58].
DR. COHEN: What is the anion composition of urine when one
produces a saluresis by interrupting renal nerve traffic?
DR. DIBONA: The predominant anion is chloride.
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DR. BRIAN DUFFY (Attending Nephrologist, Michael Reese
Hospital): In the clinical setting, many of the precipitating
causes of hepatorenal syndrome also cause volume depletion.
Does this relate to a sudden burst of renal nerve activity? And
why is it that the syndrome seems only to develop in the
hospital? Rarely does a patient enter the hospital with estab-
lished hepatorenal syndrome.
DR. DIB0NA: It is reasonable to predict that maneuvers
producing intravascular volume depletion will increase the
stimuli (underfilling hypothesis) and further acutely increase
efferent renal sympathetic nerve activity. The propensity for
the hepatorenal syndrome to develop in the hospital possibly
relates to the fact that many of the precipitating events (vigor-
ous diuresis, overzealous paracentesis, bleeding, hypotension)
occur in hospital.
DR. SUSAN FELLNER (Renal Section, Billings Hospital): Is it
possible in the experimental situation to surgically interrupt the
hepatic afferents to examine the contribution of the liver itself in
contrast to that stemming from the reduced effective blood
volume?
DR. DIBONA: This question can be pursued in experimental
hepatic cirrhosis produced by common bile duct ligation. He-
patic afferent nerves course along the hepatic artery, the portal
vein, and possibly other structures [251. An important but
difficult consideration is assessing the completeness of hepatic
denervation.
DR. STEPHEN GLUCK (Renal Section, Billings Hospital):
Have you examined whether the effects you ascribe to abnor-
malities in renal nerve function in the hepatorenal syndrome
and other diseases could be due to changes in the number of
renal alpha or beta receptors?
DR. DIBONA: The mammalian kidney contains alpha and beta
adrenoreceptors that are variously distributed on glomeruli,
vessels, and tubules. Renal hypertension or hypertension due to
DOCA and NaCI administration in rats does not alter the renal
alpha- or beta-adrenoreceptor concentration or binding affinity
[82, 83]. Abnormalities in renal alpha-i and alpha-2 adrenore-
ceptor concentration (but not binding affinities) have been
described in the spontaneously hypertensive rat and the Dahi
salt-sensitive rat [831.
DR. GARELLA: Many clinical reports claim that sodium
retention in cirrhotic patients can be alleviated by peritoneo-
venous (La Veen) shunt. Doesn't this observation argue against
a specific hepatorenal reflex?
DR. DIB0NA: Although the peritoneovenous shunt repeated-
ly has been demonstrated to induce a diuresis and a natriuresis,
most observers have noted that insertion of the shunt was
insufficient to sustain a diuresis and natriuresis and that con-
comitant diuretic therapy was required to maintain a therapeu-
tic response [73]. If the shunt can replete a diminished effective
blood volume, these observations suggest the possibility of
additional mechanisms, unrelated to the underfilling hypothe-
sis, that are involved in the renal sodium retention. In addition,
the shunt would not correct the abnormality responsible for the
increase in intrahepatic sinusoidal pressure and, by increasing
effective blood volume, actually might increase it.
DR. ALAN HALLINE (Medical Resident, Michael Reese Hos-
pital): Is there any information relating renal nerve function to
prostagiandin production? Are prostaglandins efficacious in the
hepatorenal syndrome?
DR. DIBONA: Renal nerve stimulation at intensities that do
not affect renal blood flow or produce marked renal vasocon-
striction cause increased renal prostaglandin E2 secretion [6]. In
view of the role of prostaglandins as locally active substances, it
might be preferable to seek ways of increasing renal prostaglan-
din synthesis. Prostaglandins have been given to a limited
number of patients with the hepatorenal syndrome. Administra-
tion of prostaglandin E1 in 3 patients over 1 hour failed to affect
urine volume or sodium excretion despite two- to tenfold
increases in plasma prostaglandin E concentrations [84].
DR. DIM! TRIOS EMMANOUEL (Renal Section, Billings Hospi-
tal, Chicago): Has anyone ever described a patient with Shy-
Drager syndrome who developed cirrhosis? Such an experi-
ment of nature would be an interesting test of your thesis.
DR. DIBONA: I am unaware of any reports concerning
patients with Shy-Drager syndrome who developed cirrhosis.
DR. COHEN: How do you manage patients with the hepato-
renal syndrome?
DR. DIB0NA: The patient presented today illustrates my
general approach to the clinical management of hepatorenal
syndrome. I believe it is important to exclude reversible volume
depletion by cautious intravascular volume expansion under
central cardiovascular pressure monitoring. Given the extraor-
dinarily high mortality rate in established hepatorenal syn-
drome, it is not surprising that physicians have tried a wide
variety of treatments [2]. While these have been generally
unsuccessful, the dismal natural history of hepatorenal syn-
drome justifies continued rigorous trials of newer forms of
therapy, including peritoneovenous shunting [73, 74].
DR. C0E: It is my understanding that the hepatorenal syn-
drome can be divided into two components. The first is renal
sodium retention, which can become extremely severe and can
make the patient miserable because of ascites. The second is
the fall in GFR. It has been my impression that the impact of a
fall in GFR and renal failure on mortality is not as great as is the
effect of the underlying liver disease. The latter seems to be the
limiting factor in determining the ultimate clinical outcome. Is it
your feeling that if one could correct the low GFR—by pharma-
cologic means or otherwise—that survival would be
lengthened?
DR. DIB0NA: The evidence from the clinical transplantation
experience is that the abnormality in hepatic function is the
major determinant of overall mortality [3, 58]. However, to the
extent that the decrease in GFR and accompanying hyperkale-
mia and uremic syndrome accelerate the clinical course and
decrease the time available for spontaneous improvement in
hepatic function or for hepatic transplantation, a therapeutic
intervention restoring GFR toward normal would appear to be
beneficial.
DR. FELLNER: It is a common observation that patients often
enter the hospital with reasonable baseline liver and kidney
function only to experience parallel hepatic and renal failure. Is
it possible that the neural and humoral factors that contribute to
renal ischemia and the fall in GFR also contribute to a fall in
hepatic function by decreasing hepatic blood flow? In other
words, are we seeing the added effects of hepatic ischemia
superimposed on a scarred liver?
DR. DIB0NA: Hepatic blood flow is decreased in cirrhosis
and is subject to the same neurohumoral influences that affect
the general circulation. However, because alterations in sympa-
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thetic neural outflow to vascular beds is differentiated, we
cannot assume that alterations in efferent renal sympathetic
nerve activity are associated with parallel changes in sympa-
thetic neural outflow to the hepatic vascular bed.
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Note added in proof
Further evidence of enhanced renal sympathetic nerve activity in
decompensated cirrhotic patients has been provided by Henriksen et al
(Henriksen JH, Ring-Larsen H, Kanstrup I-L, Christensen NJ:
Splanchnic and renal elimination and release of catecholamines in
cirrhosis. Evidence of enhanced sympathetic nervous activity in pa-
tients with decompensated cirrhosis. Gut in press, 1984).
Reprint requests to Dr. G. F. DiBona, Veterans Administration
Medical Center, Bldg. 3, Room 212, Iowa City, Iowa 52240, USA
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